title: Neuroprotection of ebselen against ischemia/reperfusion injury involves GABA shunt enzymes.
abstract: Seleno-organic compound, ebselen (2-phenyl-1,2-benzisoselenazol-3(2H)-one), is a substrate with radical-scavenging activity. In this study, we observed the neuroprotective effects of ebselen against ischemic damage and on GABA shunt enzymes such as glutamic acid decarboxylase 67 (GAD67), GABA transaminse (GABA-T) and succinic semialdehyde dehydrogenase (SSADH) in the hippocampal CA1 region after 5 min of transient forebrain ischemia in gerbils. For this, vehicle (physiological saline) or ebselen was administered 30 min before or after ischemia/reperfusion and sacrificed 4 days after ischemia/reperfusion. The administration of ebselen significantly reduced the neuronal death in the CA1 region induced by ischemia/reperfusion. In addition, treatment with ebselen markedly elevated GAD67, GABA-T and SSADH immunoreactivity and their protein levels compared to that in the vehicle-treated group, respectively. These results suggest that ebselen protects neurons from ischemic damage via control of the expressions of GABA shunt enzymes to enter the TCA cycle.
authors: Department of Emergency Medicine, College of Medicine, Hallym University, Chuncheon 200-702, South Korea.
authors: Jeong Yeol
authors: JY
authors: Seo
authors: Choong Hyun
authors: CH
authors: Lee
authors: Jun Hwi
authors: JH
authors: Cho
authors: Jung Hoon
authors: JH
authors: Choi
authors: Ki-Yeon
authors: KY
authors: Yoo
authors: Dae Won
authors: DW
authors: Kim
authors: Ok Kyu
authors: OK
authors: Park
authors: Hua
authors: H
authors: Li
authors: Soo Young
authors: SY
authors: Choi
authors: In Koo
authors: IK
authors: Hwang
authors: Moo-Ho
authors: MH
authors: Won
mesh_terms: D000612:4-Aminobutyrate Transaminase / Q000378:metabolism; D000818:Animals; D001393:Azoles / Q000494:pharmacology*; D015153:Blotting, Western; D002545:Brain Ischemia / Q000188:drug therapy* / Q000201:enzymology; D016923:Cell Death / Q000187:drug effects; D005849:Gerbillinae; D005968:Glutamate Decarboxylase / Q000378:metabolism; D006624:Hippocampus / Q000187:drug effects* / Q000201:enzymology; D007150:Immunohistochemistry; D054833:Isoindoles; D008124:Locomotion / Q000187:drug effects; D009474:Neurons / Q000187:drug effects* / Q000201:enzymology; D018696:Neuroprotective Agents / Q000494:pharmacology*; D016566:Organoselenium Compounds / Q000494:pharmacology*; D017966:Pyramidal Cells / Q000187:drug effects / Q000201:enzymology; D015427:Reperfusion Injury / Q000188:drug therapy*; D050644:Succinate-Semialdehyde Dehydrogenase / Q000378:metabolism; D013997:Time Factors
chemical_list: D001393:Azoles; D054833:Isoindoles; D018696:Neuroprotective Agents; D016566:Organoselenium Compounds; C042986:ebselen; D050644:Succinate-Semialdehyde Dehydrogenase; D000612:4-Aminobutyrate Transaminase; D005968:Glutamate Decarboxylase; C402565:glutamate decarboxylase 1